Pharmaceutical stocks fluctuated and adjusted. Qianyuan Pharmaceutical fell more than 10%, Kyodo Pharmaceutical fell more than 7%, and Luoxin Pharmaceutical, Hehua Co., Ltd., Erkang Pharmaceutical, and Cube Pharmaceutical had the highest declines.
Pharmaceutical stocks fluctuated and adjusted. Qianyuan Pharmaceutical fell more than 10%, Kyodo Pharmaceutical fell more than 7%, and Luoxin Pharmaceutical, Hehua Co., Ltd., Erkang Pharmaceutical, and Cube Pharmaceutical had the highest declines.
Luoxin Pharmaceutical (002793.SZ): Net loss of 366.616 million yuan in the first quarter
Gelonghui, April 26 | Luoxin Pharmaceutical (002793.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 689 million yuan, up 3.97% year on year; net profit attributable to shareholders of listed companies - 366.616 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 389.5599 million yuan; basic earnings per share - 0.03 yuan.
Express News | Forty-five stocks were traded in bulk, with Huitong New Materials leading the discount rate of 33.3%
Express News | The controlling shareholder reduced its holdings in violation of regulations, and Luoxin Pharmaceutical Co., Ltd. was warned and fined 2.8 million yuan
Luo Xin Holdings, the controlling shareholder of Luoxin Pharmaceutical (002793.SZ), received an advance notice of administrative penalties from the Zhejiang Securities Regulatory Bureau
Luo Xin Pharmaceutical (002793.SZ) announced that Luo Xin Holdings, the controlling shareholder of the company, recently received Zhejiang supervision from the China Securities Regulatory Commission...
Express News | Luoxin Pharmaceutical: The cooperation between the company and Qijun has not yet generated revenue
A-share innovative pharmaceutical stocks collectively opened higher, and many stocks such as Zhaoyan New Pharmaceutical rose and stopped
Gelonghui, March 14 | Zhaoyan Pharmaceutical, Sailong Pharmaceutical, and Luoxin Pharmaceutical rose and stopped; Zhongsheng Pharmaceutical, Hengrui Pharmaceutical, and Hisco are close to rising or stopping. Eddy Pharmaceuticals, Betta Pharmaceuticals, Biotech, Junshi Biotech, and Colon Pharmaceuticals all strengthened collectively. According to the news, a document on the “Implementation Plan for Supporting the Development of Innovative Drugs in the Whole Chain (Draft for Comments)” was distributed online, which was interpreted by the market as a major benefit for the innovative drug industry.
Luoxin Pharma Gets Right to Use Shenzhen Shishijijun Biotechnology's Fecal Microbiota Transplant Technology
Luoxin Pharmaceuticals Group (SHE:002793) agreed to receive the right to use Shenzhen Shishijijun Biotechnology's fecal microbiota transplant technology, according to a Thursday disclosure published o
Luoxin Pharmaceutical (002793.SZ) and Shenzhen Xbiome Biotech reached a strategic cooperation on commercialization of gut microbiota transplantation (FMT)
On March 7, 2024, the company signed a “Strategic Cooperation Framework Agreement” in Shenzhen with Shenzhen Xbiome Biotech Co., Ltd.
Express News | Luoxin Pharmaceutical: Signed a “Strategic Cooperation Framework Agreement” with Shenzhen Xbiome Biotech
Luoxin Pharmaceutical (002793.SZ): The repurchase was completed with a cumulative cost of 999.8861 million yuan to repurchase 26.279 million shares
Gelonghui, Feb. 19 | Luoxin Pharmaceutical (002793.SZ) announced that as of February 8, 2024, the company had repurchased a total of 26.278.61 million shares of the company through a dedicated share repurchase account, accounting for 2.39% of the company's current total share capital. Among them, the highest transaction price of the repurchase was 421 yuan/share, the minimum transaction price was 3.52 yuan/share, and the total transaction amount was 999.8861 million yuan (excluding transaction fees). At this point, the implementation of the company's share repurchase plan has been completed. The actual time range for the company to repurchase shares is from February 5, 2024 to February 8, 2024
Luoxin Pharmaceutical (002793.SZ) has repurchased 2.39% of its shares at a total cost of 99.88 million yuan
Luoxin Pharmaceutical (002793.SZ) issued an announcement. As of February 7, 2024, the company has passed a share repurchase policy...
Luoxin Pharmaceutical (002793.SZ) has repurchased a total of 1.86% of its shares at a cost of about 78.43 million yuan
Luoxin Pharmaceutical (002793.SZ) issued an announcement. As of February 6, 2024, the company has passed a share repurchase policy...
Express News | Luoxin Pharmaceutical: Plans to buy back the company's shares for 50 million yuan to 100 million yuan
Luoxin Pharmaceutical (002793.SZ): Expected net loss of 480 million yuan to 720 million yuan in 2023
On January 30, Gelonghui | Luoxin Pharmaceutical (002793.SZ) announced that it expects a net loss of 480 million yuan to 720 million yuan in 2023, after deducting non-net loss of 450 million yuan to 68 million yuan. During the reporting period, the company's profit was still at a loss, mainly because the company's innovative drug business was not able to cover its costs, and corresponding impairment preparations for inventory and long-term assets were calculated in accordance with accounting policies totaling 165.648 million yuan.
Luoxin Pharmaceuticals Posts Positive Results of Plucanatide Tablets' Trial
The phase III study of Luoxin Pharmaceuticals Group's (SHE:002793) unit, Shandong Luoxin Pharmaceutical Group, on plecanatide tablets showed positive results, the pharmaceutical company said in a Jan.
Express News | Luoxin Pharmaceutical: Phase III clinical study of procanatide tablets reached the main therapeutic end point
Luoxin Pharmaceutical (002793.SZ): As of December 20, 2023, the total number of shareholders in the company is 28256
Gelonghui December 25丨Luoxin Pharmaceutical (002793.SZ) stated on an interactive platform that as of December 20, 2023, the total number of shareholders in the company was 28,256.
Luoxin Pharmaceutical Group's innovative drug Tigolacen tablets approved for new indications to help eradicate Helicobacter pylori infection
(Pharmaceutical News, December 14, 2023) Recently, the marketing application of Luoxin Pharmaceutical Group Co., Ltd.'s key product in the field of digestive diseases and the new indication of the national class I innovative drug Tigolasen tablets (trade name: Taixinzan) “combined with appropriate antimicrobial therapy to eradicate Helicobacter pylori” was accepted by the State Drug Administration. This is the third marketing application submitted for Tigolaxen. The other two approved indications are reflux esophagitis and duodenal ulcer, respectively. The marketing application for a new indication for Helicobacter pylori infection is based on a multi-center, random, and domestic application for Tigoraxen
Combining Therapy to Eradicate Helicobacter Pylori! Luoxin Pharmaceutical's marketing application for new indications for Tigolacen tablets accepted
SHANGHAI, December 14, 2023/PRNewswire/ -- Recently, Luoxin Pharmaceutical Group Co., Ltd. (“Luoxin Pharmaceutical” for short), a key product in the field of digestive diseases, the national Class I innovative drug Tigorasan tablets (trade name: Taixinzan), a new indication for the “elimination of Helicobacter pylori in combination with appropriate antimicrobial therapy” was accepted by the State Drug Administration. This is the third marketing application submitted for Tigolaxen. The other two approved indications are reflux esophagitis and duodenal ulcer, respectively. Epidemiological studies of Helicobacter pylori infection show that more than half of the world
No Data